CASI Pharmeceuticals

Clinical

Clinical Trials

Ongoing Trials, Enrollment Closed

Product Candidate Location Principal Investigator Indication Phase
ENMD-2076 MSKCC Ghassan Abou-Alfa, MD Fibrolamellar Carcinoma II
ENMD-2076 University of CO, Denver Stephen Leong, MD Fibrolamellar Carcinoma II
ENMD-2076 Dana-Farber Cancer Inst. Rober Mayer, MD Fibrolamellar Carcinoma II
ENMD-2076 University of CA, San Francisco John Gordan, MD Fibrolamellar Carcinoma II
ENMD-2076 UT, Southwestern Muhmmad Beg, MD Fibrolamellar Carcinoma II
ENMD-2076 Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China XU, Binghe, MD TNBC II
ENMD-2076 Princess Margaret Hospital Malcolm Moore, MD Albiruni R.A. Razak, MD Advanced/Metastatic Soft Tissue Sarcoma II
ENMD-2076 Multi-center Amit M. Oza, MD Ovarian Clear Cell Carcinoma II
ENMD-2076 University of Colorado Cancer Center Jennifer Diamond, MD Triple-Negative Breast Cancer II
ENMD-2076 Indiana University Melvin and Bren Simon Cancer Center Kathy Miller, MD Triple-Negative Breast Cancer II
ENMD-2076 University of Colorado and Dana-Farber Cancer Institute Dr. Wells Messersmith & Dr. Geoffrey Shaprio Advanced Cancers I

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →

Poster

Corporate Presentation - BIO CEO & Investor Conference

Download →

Poster

Clinical Safety and Efficacy of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated, Locally Advanced or Metastatic Triple-Negative Breast Cancer

Download →